Exact Sciences Corp at JPMorgan Healthcare Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Rachel Vatnsdal - JP Morgan - Analyst : Perfect. Thank you, Kevin. So maybe first up, just question, can you explain what the QR code is behind us?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Perfect. Thank you for that. Maybe I just wanted to dig into 4Q. So you guys preannounced yesterday or earlier today with a solid announcement. Can you just kind of walk us through what were some of the drivers of growth within that fourth quarter?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Perfect. We'll dig into 2025 in a minute. But first, I just wanted to ask about Cologuard Plus. You recently secured pricing there. You plan to launch the product in a few months. So how should investors be thinking about the benefit there translating to your P&L? Really, when will those be realized? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 6:30PM, EXAS.OQ - Exact Sciences Corp at JPMorgan Healthcare Conference

Question: Rachel Vatnsdal - JP Morgan - Analyst : Maybe as a follow-up on that, just on Cologuard Plus, can you talk about -- do you expect that to be covered by Medicare? And also, do you expect it to be included in quality measures as well?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Maybe shifting over then just to MRD, I think this is an area that a lot of investors are interested in, just given the size and the speed that this market is growing at. So can you spend a minute talking about how is Exact differentiated across the competitive landscape in MRD?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Maybe shifting over then to multicancer. So can you talk to us about your strategy there? When should we expect revenue? You talked today about launching that product in 2025. So walk us through some of the color there.

Question: Rachel Vatnsdal - JP Morgan - Analyst : Maybe going off that just sticking on the topic of your commercial organization, you guys have made some recent improvements there. So can you spend a minute discussing those changes and when we should expect to see that impact?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Maybe a financial one, just in terms of the progress that you guys have made on profitability. Can you talk about the drivers there and kind of what's the trajectory that we can look at going forward?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Perfect, helpful. Then I wanted to ask on given your guys' free cash flow and also your strong balance sheet, how should investors be thinking about capital deployment going forward for Exact?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Helpful. Then how are you guys thinking about the capital structure of Exact Sciences going forward as well?

Question: Rachel Vatnsdal - JP Morgan - Analyst : Perfect. Then maybe last question, looks like we have just over or just under a minute left here. I guess you've talked about how you're comfortable with some of the sell-side estimates on 2025. So what are you guys most excited about when we look towards this year?